A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19

The requested reference [9954b2d66af87d1d613f77a3e4fb7b433d3a3af9] no longer exists in our database. It has been replaced by the current reference: [80e8966b59ae29e096012faf2520f210fce22764]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and symptoms secondary to COVID-19.
Epistemonikos ID: bc96b73a2d82dbacab21fcec6a5dd6a822b37fd1
First added on: Jun 05, 2020